Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

Patrick Y. Wen, David R. Macdonald, David A. Reardon et al. · Journal of Clinical Oncology · 2010 · 3.8K citations · Full text

Medicine, Neurology, Oncology +15

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

Henry S. Friedman, Michael D. Prados, Patrick Y. Wen et al. · Journal of Clinical Oncology · 2009 · 2.4K citations

Medicine, Oncology, Pharmacology +17

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

Teri Kreisl, Lyndon Kim, Paul Duic et al. · Journal of Clinical Oncology · 2008 · 1.6K citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

James Perry, Karl Bélanger, Warren Mason et al. · Journal of Clinical Oncology · 2010 · 385 citations

Medicine, Oncology, Pharmacology +17

Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

Philip H. Gutin, Fábio M. Iwamoto, Kathryn Beal et al. · International Journal of Radiation Oncology*Biology*Physics · 2009 · 373 citations

Medicine, Oncology, Radiation Oncology +13